Table 2 Number and incidence rate (per 1000 person-years) of tests and SARS-CoV-2 infection (positive test) following second-dose vaccination according to vaccination schedule.

From: Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

 

Heterologous

Homologous

HR/IRR

 

N / Mean

IR / SD

N / Mean

IR / SD

[95% CI]

Tested

4874

2.21/1000 py

5134

2.35/1000 py

n/a

Number of tests (overall)

0.82

1.65

0.87

1.68

1.01 [0.96–1.06]

N of tests among the tested

2.42

2.04

2.44

2.03

n/a

N of PCR tests (overall)

0.37

1.15

0.38

1.20

1.02 [0.96–1.08]

N of PCR tests among the tested

1.86

1.98

1.87

2.08

n/a

N of LFT tests overall

0.45

1.03

0.50

1.05

1.00 [0.96–1.04]

N of LFT tests among the tested

2.18

1.17

2.17

1.07

n/a

SARS-CoV-2 infection

464

0.18/1000 py

694

0.27/1000 py

0.66 [0.59–0.74]

  1. CI confidence interval, HR hazard ratio, IR incidence rate, IRR incidence rate ratio, N number, py person-years of follow-up, SD standard deviation.
Back to article page